Relationships between serum IGF-1, IGFBP-2, interleukin-1beta and interleukin-6 in inflammatory bowel disease

Hormone Research

Volumn 61, Issue 4, 2004, Pages 159-164

  Street, Maria E ^a   De'Angelis, GianLuigi ^a   Camacho Hübner, Cecilia ^b   Giovannelli, Giorgio ^a   Ziveri, Maria Angela ^a   Bacchini, Pier Luigi ^a   Bernasconi, Sergio ^a   Sansebastiano, Giuliano ^a   Savage, Martin O ^b  

^a UNIVERSITY OF PARMA   (Italy)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Crohn's disease; Inflammatory bowel disease; Insulin like growth factor binding protein 2; Insulin like growth factor I; Interleukin 1 ; Interleukin 6; Ulcerative colitis

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN C;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CROHN DISEASE; DISEASE ACTIVITY; ENTERITIS; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; INFLAMMATION; MALE; PATHOLOGICAL ANATOMY; PATIENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RELAPSE; REMISSION; SCHOOL CHILD; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHILD; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; INSULIN-LIKE GROWTH FACTOR I; INTERLEUKIN-1; INTERLEUKIN-6; MALE; RECURRENCE; REMISSION INDUCTION;

EID: 1842456977     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000075699     Document Type: Article

References (36)

1. Motil JK, Grand RJ, Davis-Kraft L, Ferlic LL, O'Brian Smith E: Growth failure in children with inflammatory bowel disease: A prospective study. Gastroenterology 1993;105:681-691.
2. Brain CE, Savage MO: Growth and puberty in chronic inflammatory bowel disease. Baillières Clin Gastroenterol 1994;8:83-100.
3. Underwood LE: Nutritional Regulation of IGF-I and IGFBPs. J Pediatr Endocrinol Metab 1996;9:303-312.
4. Ketelslegers J-M, Maiter D, Maes M, Underwood LE, Thissen J-P: Nutritional regulation of the growth hormone and insulin-like growth factor-binding proteins. Horm Res 1996;45:252-257.
5. Beattie RM, Camacho-Hübner C, Wacharasindu S, Cotterill AM, Walker-Smith JA, Savage MO: Responsiveness of IGF-I and IGFBP-3 to therapeutic intervention in children and adolescents in Crohn's disease. Clin Endocrinol (Oxf) 1998;49:483-489.
6. Banerjee K, Babinska K, Edwards R, Camacho-Hübner C, Sanderson IR, Savage MO, Croft NM: Relationship of changes in IGF-I, IGFBP-3, ALS and leptin to inflammatory and nutritional markers during enteral feeding in children with Crohn's disease. J Pediatr Gastroenterol Nutr, in press.
7. Allen DB: Growth suppression by glucocorticoid therapy. Endocrinol Metab Clin North Am 1996;25:699-717.
8. Baron J, Klein KO, Colli MJ, Yanovski JA, Novosad JA, Bacher JD, Cuttler GB: Catch up growth after glucocorticoid excess: A mechanism intrinsic to the growth plate. Endocrinology 1994;135:1367-1371.
9. Giustina A, Bussie A, Jacobello C, Wehrenberg WB: Effects of recombinant human growth hormone (GH) on bone and intermediary metabolism in patients receiving chronic glucocorticoid treatment with suppressed endogenous GH response to GH-releasing hormone. J Clin Endocrinol Metab 1995;80:122-129.
10. Gröttrup-Wolfers E, Moeller J, Karbach U, Müller-Lissner S, Endres S: Elevated cell-associated levels of interleukin-1β and interleukin 6 in inflamed mucosa of inflammatory bowel disease. Eur J Clin Invest 1996;26:115-122.
11. Schreiber S, Nikolaus S, Hampe J, Hämling J, Koop I, Groessner B, Lochs H, Raedler A : Tumour necrosis factor α and interleukin 1β in relapse of Crohn's disease. Lancet 1999;353:459-461.
12. Reimund JM, Wittersheim C, Dumont S, Muller CD, Kenney JS, Baumann R, Poindron P, Duclos B: Increased production of tumour necrosis factor-α, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease. Gut 1996;39:684-689.
13. Murch SH, Lamkin VA, Savage MO, Walker-Smith JA, MacDonald TT: Serum concentrations of tumour necrosis factor α in childhood chronic inflammatory bowel disease. Gut 1991;32:913-917.
14. Mitsuyama K, Sata M, Tanikawa K: Significance of interleukin-6 in patients with inflammatory bowel disease. Gastroenterol Jpn 1991;26:20-28.
15. Olney RC, Wilson DM, Mothai M, Fielder PJ, Smith RL: Interleukin-1 and tumor necrosis factor-alpha increase insulin-like growth factor-binding protein-3 (IGFBP-3) production and IGFBP-3 protease activity in human articular chondrocytes. J Endocrinol 1995;146:279-286.
16. Gentilini A, Feliers D, Pinzani M, Woodruff K, Abboud S: Characterization and regulation of insulin-like growth factor binding proteins in human hepatic stellate cells. J Cell Physiol 1998;174:240-250.
17. Wood TL, O'Donnell SL, Levison SW: Cytokines regulate IGF binding proteins in the CNS. Prog Growth Factor Res 1995;6:181-187.
18. Street ME, Miraki-Moud F, Sanderson IR, Savage MO, Giovannelli G, Bernasconi S, Camacho-Hübner C: Interleukin (IL)-1β and IL-6 modulate insulin-like growth factor binding protein (IGFBP) secretion in Caco-2 cells (abstract P1-214). Horm Res 2000;53(suppl 2):64.
19. Lang CH, Nystrom GJ, Frost RA: Tissue-specific regulation of IGF-I and IGF-binding proteins in response to TNFalpha. Growth Horm IGF Res 2001;11:250-260.
20. Walker-Smith JA, Sanderson IR: Diagnostic criteria for chronic inflammatory bowel disease in childhood; in Bistrian BR, Walker-Smith JA (eds): Inflammatory Bowel Diseases. Nestlé Nutr Workshop Series Clinical and Performance Programme. Vevey, Nestec/Basel, Karger, 1999, vol. 2, pp 107-120.
21. Tanner JM: Physical growth and development; in Forfar JO, Arneil GC (eds): Textbook of Paediatrics, ed 3. Edinburgh, Churchill Livingstone, 1984, pp 291-298.
22. Ferraris JR, Pennisi P, Pasqualini T, Jasper H: Effects of deflazacort immunosuppression on long-term growth and growth factors after renal transplantation. Pediatr Nephrol 1997;11:322-324.
23. Baxter RC, Holman SR, Corbould A, Stranks S, Ho PJ, Braund W: Regulation of the insulin-like growth factors and their binding proteins by glucocorticoid and growth hormone in nonislet cell tumor hypoglycemia. J Clin Endocrinol Metab 1995;802700-2708.
24. Grønbaek H, Thørgersen T, Ørskov H, Vilstrup H, Flybjerg A, Dahlerup JF: Catabolism during acute exacerbation of inflammatory bowel disease (IBD) is associated with suppressed insulin-like growth factor-I (IGF-I) and IGF binding protein 3 (IGFBP-3) levels with partial improvement during high-dose prednisone treatment and tapering (abstract P148). Growth Horm IGF Res 1999;9:380.
25. Katsanos KH, Tsatsoulis A, Christodoulou D, Challa A, Katsaraki A, Tsianos EV: Reduced serum insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 levels in adults with inflammatory bowel disease. Growth Horm IGF Res 2001;11:364-367.
26. Ballinger AB, Azooz O, El-Haj T, Poole S, Farthing MJ: Growth failure occurs through a decrease in insulin-like growth factor-I which is independent of undernutrition in a rat model of colitis. Gut 2000;46:694-700.
27. Tönshoff B, Blum WF, Wingen AM, Mehls O: Serum insulin-like growth factors (IGFs) and IGF binding proteins 1, 2, and 3 in children with chronic renal failure: Relationship to height and glomerular filtration rate. The European Study Group for Nutritional Treatment of Chronic Renal Failure in Childhood. J Clin Endocrinol Metab 1995;80:2684-2691.
28. Zumkeller W, Schwander J, Mitchell CD, Morrell DJ, Schofield PN, Preece MA: Insulin-like growth factor (IGF)-I, -II and IGF binding protein-2 (IGFBP-2) in the plasma of children with Wilm's tumour. Eur J Cancer 1993;29A:1973-1977.
29. Tönshoff B, Powell R, Zhao D, Durham SK, Coleman ME, Domené HM, Blum WF, Baxter RC, Moore LC, Kaskel FJ: Decreased hepatic insulin-like growth factor (IGF)-I and increased IGF binding protein-1 and -2 gene expression in experimental uremia. Endocrinology 1997;138:938-946.
30. Hoeflich A, Wu M, Mohan S, Foll J, Wanke R, Froelich T, Arnold GJ, Lahm H, Kolb HJ, Wolf E: Overexpression of insulin-like growth factor-binding protein-2 in transgenic mice reduces postnatal body weight gain. Endocrinology 1999;140:5488-5496.
31. Ulinski T, Powell DR, Seck T, Pfeilschifter J, Mehls O, Tönshoff B: Differential effects of insulin-like growth factor-binding proteins (IGFBPs) on IGF activity in growth plate chondrocytes (abstract OC14.3). Growth Horm IGF Res 1999;9:326.
32. Clemmons DA, Snyder DK, Busby WH Jr: Variables controlling the secretion of insulin-like growth factor binding protein-2 in normal human subjects. J Clin Endocrinol Metab 1991;73:727-723.
33. Holmes RP, Holly JM, Soothill PW: Maternal serum insulin-like growth factor binding protein-2 and -3 and fetal growth. Hum Reprod 1999;14:1879-1884.
34. De Benedetti F, Meazza C, Oliveri M, Pignatti P, Vivarelli M, Alonzi T, Fattori E, Garrone S, Barreca A, Martini A: Effect of IL-6 on IGF binding protein-3:A study in IL-6 transgenic mice and in patients with systematic juvenile idiopathic arthritis. Endocrinology 2001;142:4818-4826.
35. Mahida YR, Kurlac L, Gallagher A, Hawkey CJ: High circulating concentrations of interleukin-6 in active Crohn's disease but not ulcerative colitis. Gut 1991;32:1531-1534.
36. Gross V, Andus T, Caesar I, Roth M, Scholmerich J: Evidence for continuous stimulation of interleukin-6 production in Crohn's disease. Gastroenterology 1992;102:514-519.